Transcription Factor Drug Development | Kisaco Research
Please click here for KR Covid-19 Update

Translating Transcription Factor-Druggable Approaches into Safe and Effective Therapeutics

Download the Agenda
Basel, Switzerland
7-8 July, 2020

“This conference will give us the unique and diverse perspectives to develop novel therapeutic modalities within the oncogenic transcription factor drug development field. ”

– Joey Azofeifa, CEO, Arpeggio Bio

“I am looking forward to sharing new data at this event and meeting with other pharma & biotech companies at this first TF-targeting conference.”

– Dr. Liandong Ma, President & VP of the Institute of R&D, Kintor Pharmaceuticals

Why Attend

With an increasing number of projects entering the pipeline both clinically and pre-clinically aimed at targeting transcription factors that were previously thought to be “undruggable”, the industry is ready to develop further insight into the commercialization of TF-based therapeutics within cancer and other disease settings. With multiple strategies having entered the clinic from PPI inhibitors, modulators of TF expression, and the first PROTAC-based degraders, it could only be a matter of time before the first therapy enters the market.

The inaugural Transcription Factor Drug Development Congress is the first of its kind anywhere in the world! 

We will bring together leading industry players within large pharma and biotech, along with expert academics in the oncology drug discovery space – providing an open forum to facilitate the sharing of in vitro and in vivo data, as well as build a deeper understanding of transcriptional machinery to make the ‘undruggable’ druggable.

Expect to hear strategies to overcome the structural biology, pharmacology, and chemistry obstacles in the design and development of TF-based therapeutics by hearing real success stories in the targeting of transcription factors for therapeutic benefit.

Develop further insight into targeting MYC, STAT, and other transcription factors with a role in disease. 

Talk to Our Speakers About

  • Assay development
  • TF-inhibitor PK determination
  • PPI inhibitor and PROTAC-based degrader development
  • Modulators of transcription factor gene expression
  • Risk vs benefit; understanding the risks of TF-based therapeutics in normal cells
  • Success stories in targeting transcription factors
  • TF-inhibitor-kinase inhibitor combinations and targeting TF RNA
  • Overcoming protein-DNA and protein-protein binding challenges
  • Strategies to identify new TF targets
  • Case studies from within the clinic

Confirmed 2020 Speakers

 

Daniel Nomura

Associate Professor of Chemical Biology
UC Berkeley

Dan Nomura is an associate professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. He is also an associate adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. Dr. Nomura is also an editor for Cell Chemical Biology and Current Protocols in Chemical Biology. He earned his B.A. in Molecular and Cell Biology and Ph.D.

Daniel Nomura

Associate Professor of Chemical Biology
UC Berkeley

Daniel Nomura

Associate Professor of Chemical Biology
UC Berkeley

Dan Nomura is an associate professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. He is also an associate adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. Dr. Nomura is also an editor for Cell Chemical Biology and Current Protocols in Chemical Biology. He earned his B.A. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology with Professor John Casida at UC Berkeley and was a postdoctoral fellow at The Scripps Research Institute in chemical physiology with Professor Ben Cravatt before returning to UC Berkeley as a faculty member in 2011. Among his honors are selection as a Searle Scholar, American Cancer Society Research Scholar Award, the Department of Defense Breakthroughs Award, and the Mark Foundation for Cancer Research INSPIRE award. Research in the Nomura Research Group is focused on reimagining druggability using chemoproteomic platforms to discover new disease therapies. 

 

Liandong Ma

VP and President of the Institute of R&D
Suzhou Kintor Pharmaceuticals, Inc

Liandong Ma

VP and President of the Institute of R&D
Suzhou Kintor Pharmaceuticals, Inc

Liandong Ma

VP and President of the Institute of R&D
Suzhou Kintor Pharmaceuticals, Inc
 

Opher Gileadi

Principal Investigator Structural Genomics Consortium,
University of Oxford

Opher Gileadi

Principal Investigator Structural Genomics Consortium,
University of Oxford

Opher Gileadi

Principal Investigator Structural Genomics Consortium,
University of Oxford
 

Joey Azofeifa

Chief Executive Officer
Arpeggio Bio

Joey Azofeifa

Chief Executive Officer
Arpeggio Bio

Joey Azofeifa

Chief Executive Officer
Arpeggio Bio
 

Laura Soucek

Chief Executive Officer; Principle Investigator
Peptomyc; VHIO

Laura Soucek

Chief Executive Officer; Principle Investigator
Peptomyc; VHIO

Laura Soucek

Chief Executive Officer; Principle Investigator
Peptomyc; VHIO
 

Paul Workman

Chief Executive and President
The Institute of Cancer Research

Paul Workman

Chief Executive and President
The Institute of Cancer Research

Paul Workman

Chief Executive and President
The Institute of Cancer Research
 

Longchuan Bai

Assistant Research Professor
University of Michigan

Longchuan Bai

Assistant Research Professor
University of Michigan

Longchuan Bai

Assistant Research Professor
University of Michigan
 

Charles Lin

Vice President of Biology
Kronos Bio, Inc.

Charles Lin

Vice President of Biology
Kronos Bio, Inc.

Charles Lin

Vice President of Biology
Kronos Bio, Inc.
 

Angela Koehler

Associate Professor, Biological Engineering
MIT

Angela Koehler

Associate Professor, Biological Engineering
MIT

Angela Koehler

Associate Professor, Biological Engineering
MIT
 

Dr Raj Chopra

Head of Cancer Therapeutics
The Institute of Cancer Research

Dr Raj Chopra

Head of Cancer Therapeutics
The Institute of Cancer Research

Dr Raj Chopra

Head of Cancer Therapeutics
The Institute of Cancer Research
 

Martin Eilers

Principal Investigator
University of Würzburg

Martin Eilers

Principal Investigator
University of Würzburg

Martin Eilers

Principal Investigator
University of Würzburg
 

David Drewery

Research Associate Professor
Strategic Genomics Consortium UNC

David Drewery

Research Associate Professor
Strategic Genomics Consortium UNC

David Drewery

Research Associate Professor
Strategic Genomics Consortium UNC
 

Steve Bellon

SVP, Drug Discovery
Foghorn Therapeutics

Steve Bellon

SVP, Drug Discovery
Foghorn Therapeutics

Steve Bellon

SVP, Drug Discovery
Foghorn Therapeutics
 

Nicolas Thomä

Senior Group Leader
Friedrich Miescher Institute for Biomedical Research

My laboratory has set out to combine structural biology, cell biology and complex biochemical in vitro reconstitutions to address the molecular workings of these chromatin-bound complex assemblies. Our focus is on machines that detect and repair mutations in the DNA, and those that make possible the accurate passage of epigenetic information to the daughter generation.

Nicolas Thomä

Senior Group Leader
Friedrich Miescher Institute for Biomedical Research

Nicolas Thomä

Senior Group Leader
Friedrich Miescher Institute for Biomedical Research

My laboratory has set out to combine structural biology, cell biology and complex biochemical in vitro reconstitutions to address the molecular workings of these chromatin-bound complex assemblies. Our focus is on machines that detect and repair mutations in the DNA, and those that make possible the accurate passage of epigenetic information to the daughter generation.

 

Eric Fischer

Assistant Professor of Biological Chemistry
Harvard Medical School

Eric Fischer, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute. His research focuses on understanding the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in disease. His work further focuses on new therapeutic approaches such as targeted protein degradation.

Eric Fischer

Assistant Professor of Biological Chemistry
Harvard Medical School

Eric Fischer

Assistant Professor of Biological Chemistry
Harvard Medical School

Eric Fischer, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute. His research focuses on understanding the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in disease. His work further focuses on new therapeutic approaches such as targeted protein degradation. He co-directs the DFCI Center for Protein Degradation and has been recognized for his pioneering work on the structure of cereblon and the mechanism of action of thalidomide.

 

Ali Tassavoli

Professor of Chemical Biology
University of Southampton

Ali Tassavoli

Professor of Chemical Biology
University of Southampton

Ali Tassavoli

Professor of Chemical Biology
University of Southampton
 

Patrick Matthias

Senior Group Leader, Epigenetics
Friedrich Miescher Institute for Biomedical Research

Patrick Matthias

Senior Group Leader, Epigenetics
Friedrich Miescher Institute for Biomedical Research

Patrick Matthias

Senior Group Leader, Epigenetics
Friedrich Miescher Institute for Biomedical Research
 

Robert Konrat

Group Leader, Computational Biology & Biomolecular NMR Spectroscopy
The Max Perutz Labs, University of Vienna

Robert Konrat

Group Leader, Computational Biology & Biomolecular NMR Spectroscopy
The Max Perutz Labs, University of Vienna

Robert Konrat

Group Leader, Computational Biology & Biomolecular NMR Spectroscopy
The Max Perutz Labs, University of Vienna
 

Allan Jordan

Director, Oncology Drug Discovery
Sygnature Discovery

Allan Jordan

Director, Oncology Drug Discovery
Sygnature Discovery

Allan Jordan

Director, Oncology Drug Discovery
Sygnature Discovery
 

Will West

Founder & Chief Executive Officer
CellCentric

Will West

Founder & Chief Executive Officer
CellCentric

Will West

Founder & Chief Executive Officer
CellCentric
 

Christopher Ott

Principal Investigator, Center for Cancer Research
Massachusetts General Hospital

Christopher Ott

Principal Investigator, Center for Cancer Research
Massachusetts General Hospital

Christopher Ott

Principal Investigator, Center for Cancer Research
Massachusetts General Hospital
 

Dr John Schneekloth

Jr. Principal investigator
National Cancer Institute-Frederick

Dr John Schneekloth

Jr. Principal investigator
National Cancer Institute-Frederick

Dr John Schneekloth

Jr. Principal investigator
National Cancer Institute-Frederick
 

Giorgio Galli

Lab Head Target Identification & Validation,
NIBR, Novartis

Giorgio Galli

Lab Head Target Identification & Validation,
NIBR, Novartis

Giorgio Galli

Lab Head Target Identification & Validation,
NIBR, Novartis

Attendees From Our Undruggables Series

Download the Agenda

The inaugural Transcription Factor Drug Development Congress is the first of its kind anywhere in the world.

We will bring together leading industry players within large pharma and biotech along with expert academics in the oncology drug discovery space – providing an open forum to facilitate the sharing of in vitro and in vivo data, as well as build a deeper understanding of transcriptional machinery to make the ‘undruggable’ druggable.

Expect to hear strategies to overcome the structural biology, pharmacology, and chemistry obstacles in the design and development of TF-based therapeutics by hearing real success stories in the targeting of transcription factors for therapeutic benefit.

Here's a glimpse of what to expect: 

Download the full agenda here

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase in

Tuesday, March 3, 2020 to Friday, April 10, 2020
Super Early Bird - Academics, Students & Post-Doctoral Researchers
€ 799.00
Super Early bird ends 10th April 2020. Save €300.
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Chris Stefanov, [email protected]
Tuesday, March 3, 2020 to Friday, April 10, 2020
Super Early Bird - Pharma & Biotech
€ 1,299.00
Super Early bird ends 10th April 2020. Save €700.
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Chris Stefanov, [email protected]
Tuesday, March 3, 2020 to Friday, April 10, 2020
Super Early Bird - Service Providers, CROs & Vendors
€ 1,899.00
Super Early bird ends 10th April 2020. Save €600.
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
To increase your brand presence, contact Chris Stefanov, [email protected]
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.